BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 24686242)

  • 1. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.
    Blat D; Zigmond E; Alteber Z; Waks T; Eshhar Z
    Mol Ther; 2014 May; 22(5):1018-28. PubMed ID: 24686242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.
    Elinav E; Waks T; Eshhar Z
    Gastroenterology; 2008 Jun; 134(7):2014-24. PubMed ID: 18424268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes.
    Tenspolde M; Zimmermann K; Weber LC; Hapke M; Lieber M; Dywicki J; Frenzel A; Hust M; Galla M; Buitrago-Molina LE; Manns MP; Jaeckel E; Hardtke-Wolenski M
    J Autoimmun; 2019 Sep; 103():102289. PubMed ID: 31176558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8
    Cagnoni AJ; Giribaldi ML; Blidner AG; Cutine AM; Gatto SG; Morales RM; Salatino M; Abba MC; Croci DO; Mariño KV; Rabinovich GA
    Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MondoA-Thioredoxin-Interacting Protein Axis Maintains Regulatory T-Cell Identity and Function in Colorectal Cancer Microenvironment.
    Lu Y; Li Y; Liu Q; Tian N; Du P; Zhu F; Han Y; Liu X; Liu X; Peng X; Wang X; Wu Y; Tong L; Li Y; Zhu Y; Wu L; Zhang P; Xu Y; Chen H; Li B; Tong X
    Gastroenterology; 2021 Aug; 161(2):575-591.e16. PubMed ID: 33901495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
    Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
    Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The other face of chimeric antigen receptors.
    Dotti G
    Mol Ther; 2014 May; 22(5):899-900. PubMed ID: 24787977
    [No Abstract]   [Full Text] [Related]  

  • 9. RORγt-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells.
    Rizzo A; Di Giovangiulio M; Stolfi C; Franzè E; Fehling HJ; Carsetti R; Giorda E; Colantoni A; Ortenzi A; Rugge M; Mescoli C; Monteleone G; Fantini MC
    Cancer Immunol Res; 2018 Sep; 6(9):1082-1092. PubMed ID: 29991500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
    Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
    Front Immunol; 2018; 9():2359. PubMed ID: 30369931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice.
    Bézie S; Charreau B; Vimond N; Lasselin J; Gérard N; Nerrière-Daguin V; Bellier-Waast F; Duteille F; Anegon I; Guillonneau C
    Blood Adv; 2019 Nov; 3(22):3522-3538. PubMed ID: 31730699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study.
    Qian S; Chen J; Zhao Y; Zhu X; Dai D; Qin L; Hong J; Xu Y; Yang Z; Li Y; Guijo I; Jiménez-Galanes S; Guadalajara H; García-Arranz M; García-Olmo D; Shen J; Villarejo-Campos P; Qian C
    Cytotherapy; 2024 Feb; 26(2):113-125. PubMed ID: 37999667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Intestinal Inflammation With Epicutaneous Immunotherapy Requires TGF-β and IL-10 but Not Foxp3
    Chen X; Berin MC; Gillespie VL; Sampson HA; Dunkin D
    Front Immunol; 2021; 12():637630. PubMed ID: 33717186
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
    Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE
    Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology.
    Koristka S; Kegler A; Bergmann R; Arndt C; Feldmann A; Albert S; Cartellieri M; Ehninger A; Ehninger G; Middeke JM; Bornhäuser M; Schmitz M; Pietzsch J; Akgün K; Ziemssen T; Steinbach J; Bachmann MP
    J Autoimmun; 2018 Jun; 90():116-131. PubMed ID: 29503042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?
    Janssens I; Cools N
    Cell Immunol; 2020 Dec; 358():104236. PubMed ID: 33137651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the inherent power of chimeric antigen receptor (CAR)-expressing regulatory T cells (CAR-Tregs) to treat autoimmune-related disorders.
    Kahmini FR; Shahgaldi S
    Mol Biol Rep; 2022 May; 49(5):4069-4078. PubMed ID: 35534581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA
    Zhang C; Wang Z; Yang Z; Wang M; Li S; Li Y; Zhang R; Xiong Z; Wei Z; Shen J; Luo Y; Zhang Q; Liu L; Qin H; Liu W; Wu F; Chen W; Pan F; Zhang X; Bie P; Liang H; Pecher G; Qian C
    Mol Ther; 2017 May; 25(5):1248-1258. PubMed ID: 28366766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
    Parkhurst MR; Yang JC; Langan RC; Dudley ME; Nathan DA; Feldman SA; Davis JL; Morgan RA; Merino MJ; Sherry RM; Hughes MS; Kammula US; Phan GQ; Lim RM; Wank SA; Restifo NP; Robbins PF; Laurencot CM; Rosenberg SA
    Mol Ther; 2011 Mar; 19(3):620-6. PubMed ID: 21157437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.
    Terry LV; Oo YH
    Front Immunol; 2020; 11():565518. PubMed ID: 33072105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.